Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting<i>ALK</i>and<i>ROS1</i>Fusion and Resistance Mutations in Patients With Non–Small-Cell Lung Cancer

Abstract

Next-generation, targeted, amplicon-based sequencing for liquid biopsy specimen profiling provides clinically relevant detection of <i>ALK/ROS1</i> fusions in TKI-naïve patients and allows for the identification of resistance mutations in patients treated with TKIs. Liquid biopsy specimens from patients treated with TKIs may affect clinical outcomes and capture heterogeneity of TKI resistance, supporting their role in selecting sequential therapy.